Aslan Pharmaceuticals Ltd.

( )
ASLN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
REGNRegeneron Pharmaceuticals, Inc. -1.98%555.792.7%$638.53m
GILDGilead Sciences, Inc. -0.32%58.531.0%$575.75m
AMGNAmgen, Inc. 0.67%217.821.3%$570.79m
VRTXVertex Pharmaceuticals, Inc. -0.64%207.011.9%$530.76m
MRNAModerna, Inc. 8.43%71.280.0%$450.52m
ILMNIllumina, Inc. 1.68%314.903.5%$403.92m
EXASEXACT Sciences Corp. -5.50%120.5120.7%$281.24m
ALXNAlexion Pharmaceuticals, Inc. 2.93%118.212.0%$267.42m
NVAXNovavax, Inc. 7.75%87.6396.5%$256.83m
BIIBBiogen, Inc. 0.50%245.481.7%$252.35m
BNTXBioNTech SE 9.38%84.810.0%$216.73m
SRRKScholar Rock Holding Corp. -6.84%40.460.0%$163.02m
SGENSeagen Inc. -1.29%192.346.0%$143.09m
SRNESorrento Therapeutics, Inc. 2.68%7.281.4%$139.14m
CRSPCRISPR Therapeutics AG 1.73%96.350.6%$125.52m

Company Profile

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company, which engages in the development of novel therapeutics. Its pipeline includes varlitinib, ASLAN003, ASLAN004, and ASLAN002. The firm's portfolio focuses on validated growth pathways applied to new patient segments, novel immune checkpoints, and novel cancer metabolic pathways. The company was founded by Carl Aslan Jason Morton Firth, Mark McHale, and Jeffrey Tomlinson in 2010 and is headquartered in Singapore.